December 2
Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals for Phase II Combination Study in Patients Chronically Infected with Hepatitis C
December 1
NPS Pharmaceuticals Completes Submission of New Drug Application for GATTEX(R) (teduglutide) in Adult Short Bowel Syndrome (SBS)
Aegerion Pharmaceuticals to Participate in the 2011 Deutsche Bank BioFEST Conference
Amicus Therapeutics Announces First Patient in Phase 2 Study for Pompe Disease
Celldex Initiates ACT IV, a Pivotal International Phase 3 Trial of Rindopepimut in Patients with Glioblastoma
Cyclacel to Webcast Analyst & Institutional Investor Meeting Wednesday, December 7, 2011
Senesco Receives Milestone Payment from Bayer CropScience
November 30
Unigene’s Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
CircuLite® Raises $30 Million Series D Financing
Alvin Ailey American Dance Theater Premieres Home, a New Work Inspired by the Winning Photos and Essays from the 2011 REYATAZ®(atazanavir sulfate) “Fight HIV Your Way” Contest, an Initiative of Bristol-Myers Squibb
The Medicines Company to Participate in the 2011 Deutsche Bank BioFEST
November 29
Alliance Life Sciences Issues White Paper: “Federal and State Sunshine Act Compliance Readiness” Addresses Lack of Direction from CMS
NPS Pharmaceuticals to Present at Deutsche Bank BioFEST Conference
FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
November 25
Celgene Corporation to Present at the Piper Jaffray Health Care Conference 2011
November 23
A Tribute to Alex Barkas
Advaxis Completes Pre-IND Meeting for ADXS-HER2
November 22
Lexicon Announces Commencement of Rights Offering to Stockholders
Senesco to Present at NYSSA’s 2011 Biotech / Specialty Pharma Conference
Bio-Reference Laboratories, Inc. and McKesson Specialty Health’s Onmark GPO Execute Purchasing Agreement
Pacira Pharmaceuticals, Inc. Announces Completion of Follow-on Offering of Common Stock and Exercise of Over-Allotment Option
November 21
Celldex Therapeutics Reports Positive Mature Survival Data from Rindopepimut Phase 2 Brain Cancer Study at SNO 2011
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
Savara Inc. Joins SAFE-BioPharma Association
Hoping Pharmasset Gains Jobs After Being Sold to Calif. Biotech in $11B deal
November 18
Bio-Reference Laboratories’ CEO Marc Grodman MD Speaks at Capitol Hill Policy Forum on the Contribution Genetic Tests Are Making to Cancer Care
November 17
Edge Therapeutics Appoints James J. Loughlin to Board of Directors
Bristol-Myers Squibb Foundation Awards $2.34 Million in Grants to Help Prisoners with Mental Illness Return to Community
November 16
Unigene Strengthens Board with the Appointment of Walgreen’s Executive, Thomas J. Sabatino, Jr.-Board Strengthened with Extensive Healthcare and Legal Expertise-
Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients with Type 2 Diabetes
November 15
Immunomedics Awarded Additional U.S. Patent for Anti-Cd20 Treatment of Autoimmune Diseases
Bio-Reference Laboratories Named 8th Fastest Growing Company in State of New Jersey
Advaxis Licenses Novel Antigen for Severe Breast Cancer and Other Tumor Types
November 14
Bristol-Myers Squibb Foundation’s Together on Diabetes® Initiative Marks First Anniversary by Awarding $18.4 Million in Grants to Help Communities Hardest Hit by Diabetes, Issuing Annual Report
Unigene Announces Novartis’ Disclosure of First Interpretable Results from Phase 3 Trial of Calcitonin (SMC021) in the Treatment of Post-menopausal Osteoporosis
DuPont Crop Protection and BioLeap Enter Research Collaboration
Soligenix Reports Third Quarter 2011 Financial Results
Cyclacel Pharmaceuticals Reports Third Quarter 2011 Financial Results
Pharmasset Reports Fiscal Year End 2011 Financial Results
The Medicines Company’s MDCO-216 (ApoA-I Milano Complex) Demonstrates Capacity to Clear Cholesterol from Cells in Preclinical Model
November 13
New Data Presented on Phase 3 Trial Of ELIQUIS®(apixaban) in the Prevention of Venous Thromboembolism in Patients with Acute Medical Illness
Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
November 12
Enzon Presents Clinical and Preclinical Data on mRNA Antagonists at 2011 AACR-NCI-EORTC Meeting
November 11
Derma Sciences Reports Third Quarter Financial and Operating Results; End-of-Phase 2 Meeting Set with FDA
Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz®(atazanavir sulfate) in Brazil
Immunomedics Receives Thomas Alva Edison Patent Award from Research & Development Council Of New Jersey
Bio-Reference Laboratories, Inc. Announces Stock Buy-Back Plan
Lexicon Announces Plans for Rights Offering to Stockholders
November 10
CorMedix Reports Third Quarter 2011 Results
November 9
Amicus Therapeutics to Present at Lazard Capital Markets 8th Annual Healthcare Conference on Wednesday, November 16, 2011
